PHARMACEUTICAL USE OF CORD BLOOD IMMUNOSUPPRESSIVE CELL

• Main Authors: SOHN, Hyun Jung, LIM, Bang Geul, KIM, Eun Ah, KIM, Su Eon, CHO, Hyun Il, JUNG, Soo Hyun, KIM, Tai Gyu
• Format: Patent
• Language: English; French; Korean
• Published: 22.12.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in accordance with analysis of function and phenotype and a classification standard, as a new cell therapy product for anti-inflammation, anti-fibrosis, and prevention or treatment of myocardial infarction. La présente invention concerne l'utilisation pharmaceutique d'une cellule immuno-suppressive de sang de cordon et, plus spécifiquement, la présente invention concerne l'utilisation d'une cellule immuno-suppressive de sang de cordon d'origine humaine, qui est sélectionnée conformément à l'analyse de la fonction et du phénotype et à une norme de classification, en tant que nouveau produit de thérapie cellulaire pour l'anti-inflammation, l'anti-fibrose, et la prévention ou le traitement d'un infarctus du myocarde. 본 발명은 제대혈면역억제세포의 약제학적 용도에 관한 것으로, 보다 상세하게는, 본 발명은 기능과 표현형의 분석 및 구분 기준에 따라 선별된 인간 유래 제대혈면역억제세포의 항염증, 항섬유화, 심근경색의 예방 또는 치료를 위한 새로운 세포치료제로서의 용도를 제공한다.